A rare clinical case: treatment of a mediastinal tumor without organospecificity

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The incidence of malignant neoplasms is steadily increasing every year. In addition to common localizations, oncologists encounter non-standard tumors that require a personalized approach to treatment depending on the clinical situation. In recent decades, there has been significant progress in the creation of pharmacological drugs that are successfully used in the treatment of cancer, which selectively affect various targets in tumor cells. The article presents a clinical case of diagnosis and treatment of an anterior mediastinal tumor without organospecificity. An effective option for drug therapy aimed at targets found in tumor cells is described. The presented example demonstrates an individualized approach to the choice of treatment for a cancer patient and the effectiveness of its use.

全文:

受限制的访问

作者简介

Yaroslavna Yakimenko

Astrakhan State Medical University; Regional Clinical Oncology Dispensary

编辑信件的主要联系方式.
Email: maleeva.yaroslavna@yandex.ru
ORCID iD: 0000-0002-2276-2562
SPIN 代码: 7642-6150

Postgraduate Student, Department of Oncology and Radiation Therapy, Astrakhan State Medical University

俄罗斯联邦, Astrakhan; Astrakhan

V. Kutukov

Astrakhan State Medical University; Regional Clinical Oncology Dispensary

Email: maleeva.yaroslavna@yandex.ru
ORCID iD: 0000-0002-8167-2997
俄罗斯联邦, Astrakhan; Astrakhan

S. Gavrilova

Regional Clinical Oncology Dispensary

Email: maleeva.yaroslavna@yandex.ru
ORCID iD: 0009-0004-7602-1243
俄罗斯联邦, Astrakhan

K. Rotar

Astrakhan State Medical University

Email: maleeva.yaroslavna@yandex.ru
ORCID iD: 0009-0000-9522-9665
俄罗斯联邦, Astrakhan

参考

  1. Li B., Chan H. L., Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019;26(17):3009–3025. doi: 10.2174/0929867324666170804143706.
  2. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. doi: 10.1038/s41467-020-17670-y.
  3. Gunturi A., McDermott D. F. Nivolumab for the treatment of cancer. Expert Opin Investig Drugs. 2015;24(2):253–260. doi: 10.1517/13543784.2015.991819.
  4. Sundar R., Cho B. C., Brahmer J.R., Soo R. A. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):85–96. doi: 10.1177/1758834014567470.
  5. Darvin P., Toor S. M., Sasidharan Nair V., Elkord, E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12): 1–11. doi: 10.1038/s12276-018-0191-1.
  6. de Miguel M., Calvo E. Clinical challenges of immune checkpoint inhibitors. Cancer Cell. 2020;8(3):326–333. doi: 10.1016/j.ccell.2020.07.004.
  7. Shiravand Y., Khodadadi F., Kashani S.M.A., et al. Immune checkpoint inhibitors in cancer therapy. Current Oncol. 2022;29(5):3044–3060. doi: 10.3390/curroncol29050247.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2024